

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 June 2023 (22.06.2023)



(10) International Publication Number
WO 2023/110727 A3

(51) International Patent Classification:

A61K 47/60 (2017.01) A61P 35/00 (2006.01)

A61K 47/69 (2017.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(21) International Application Number:

PCT/EP2022/085347

(22) International Filing Date:

12 December 2022 (12.12.2022)

(88) Date of publication of the international search report:

03 August 2023 (03.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/288,957 13 December 2021 (13.12.2021) US

22205987.5 08 November 2022 (08.11.2022) EP

(71) Applicant: ASCENDIS PHARMA ONCOLOGY
DIVISION A/S [DK/DK]; Tuborg Boulevard 12, 2900
Hellerup (DK).

(72) Inventors: MILLER BREINHOLT, Vibeke; c/o As-
cendis Pharma A/S, Tuborg Boulevard 12, 2900 Hellerup
(DK). SINGEL, Stina; c/o Ascendis Pharma Inc., 1000
Page Mill Road, Palo Alto, California 94304 (US).

(74) Agent: BÜCHEL, Edwin; Patentanwälte Isenbruck Bösl
Hörschler PartG mbB, Seckenheimer Landstraße 4, 68163
Mannheim (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CANCER TREATMENTS WITH TLR7/8 AGONISTS

(57) Abstract: The present invention relates to a unit dosage form comprising a therapeutically effective amount of a TLR7/8 agonist conjugate or a pharmaceutically acceptable salt thereof; to a TLR7/8 agonist conjugate for use in the treatment of cancer, wherein the TLR7/8 agonist conjugate is administered via intratumoral administration in a dose ranging from 0.3 mg to 3 mg of TLR7/8 agonist per tumor; and to specific conjugates of resiquimod and related aspects.

WO 2023/110727 A3